| Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. | Eli Lilly follows up MiNA pact with a 2nd $1B-plus RNA collab, this time with ProQR No joy for Ajovy: Teva's migraine drug can't find a win in meta-analysis versus Biohaven, AbbVie meds Judge rules 'neigh' on using ivermectin for COVID-19, reversing earlier court decision GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent Healthcare bankruptcies at all-time low, new report finds As Congress considers drug price reforms, Merck, Lilly and Takeda execs warn of dire consequences Smiths shuns previous medtech deal, instead opting for $2.4B from ICU Medical Clover Health to integrate Assistant tool into athenahealth electronic medical record COVID-19 tracker: Europe lists Guillain-Barré syndrome as rare AZ side effect; Novavax trials combined flu, coronavirus shot Experts say adding dental coverage to Medicare won't trigger major shift away from Medicare Advantage Glympse Bio names first medical chief, offering a peek at the clinical future of its disease-spotting biosensors Featured Story By Ben Adams Eli Lilly is doubling down on RNA research as it pens another major biobucks pact with a small but promising biotech in the gene-silencing space. read more |
| |
---|
| Top Stories By Noah Higgins-Dunn A new analysis from Teva pitting its long-acting migraine injectable Ajovy against oral rivals from Biohaven Pharmaceuticals and AbbVie doesn’t appear to separate its med from the up-and-comers as hoped. read more By Dave Muoio An Ohio judge said hospitals should not be forced to administer ivermectin, a drug best known as a horse dewormer, for COVID-19 patients as there is no conclusive medical or scientific evidence supporting its use for the virus. The patient in question, however, still received the treatment for 13 days due to an earlier temporary decision. read more By Eric Sagonowsky While COVID-19 vaccines set all sorts of industry launch records, another potential megablockbuster vaccine market looms on the horizon. Some of pharma's top players, including Pfizer, Johnson & Johnson and GlaxoSmithKline are expected to be involved, one prominent industry analyst writes. read more By Emmy Lucas Attralus Therapeutics has scored $116 million to bring a handful of amyloidosis therapies into the clinic along with an accompanying radiotracer diagnostic imaging agent. read more By Anastassia Gliadkovskaya The second quarter of this year was the lowest the Health Care Services Distress Research Index had ever recorded, according to a new report. read more By Kevin Dunleavy As Congress considers sweeping legislation that would allow the government to negotiate prices for prescription drugs, industry execs are warning of dire consequences. For their part, employer and public interest groups are pushing for change that they view as now-or-never. read more By Conor Hale After unveiling plans last month to sell its medical device business for $2 billion, the U.K. technology group announced that a better deal has come along from a once-previous suitor. read more By Paige Minemyer Clover Health is integrating its Clover Assistant into athenahealth electronic health records, the startup insurer announced Wednesday. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Europe's drug regulator listed Guillain-Barré syndrome as a potential rare side effect for AstraZeneca's pandemic vaccine. Pfizer picked a low vaccine dose on purpose, its chief scientist said. Plus more headlines. read more By Robert King Experts say adding dental coverage to traditional Medicare likely won't lead to a massive shift away from Medicare Advantage, but industry concerns about payment structures persist. read more By Andrea Park Helping Glympse along its path through clinical trials, FDA approval and beyond will be Tram Tran, M.D., who joins the Cambridge, Mass.-based company as its first-ever chief medical officer. read more |